Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Equities research analysts at Wedbush boosted their FY2025 EPS estimates for Fennec Pharmaceuticals in a report released on Monday, March 10th. Wedbush analyst D. Nierengarten now anticipates that the biopharmaceutical company will earn $0.79 per share for the year, up from their previous forecast of $0.66. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. Wedbush also issued estimates for Fennec Pharmaceuticals' FY2027 earnings at $4.10 EPS.
Separately, Stephens raised Fennec Pharmaceuticals to a "strong-buy" rating in a report on Monday, November 18th.
View Our Latest Stock Analysis on FRX
Fennec Pharmaceuticals Price Performance
FRX stock opened at C$9.26 on Wednesday. The company has a market capitalization of C$178.58 million, a P/E ratio of -156.86 and a beta of 0.25. Fennec Pharmaceuticals has a twelve month low of C$5.65 and a twelve month high of C$15.20. The business has a 50 day simple moving average of C$9.19 and a 200-day simple moving average of C$7.90. The company has a current ratio of 7.80, a quick ratio of 10.17 and a debt-to-equity ratio of -620.83.
Insider Buying and Selling
In other news, Director Rostislav Christov Raykov sold 10,000 shares of the firm's stock in a transaction on Monday, January 6th. The stock was sold at an average price of C$8.76, for a total value of C$87,552.00. Insiders sold a total of 21,186 shares of company stock valued at $196,017 over the last three months. 16.20% of the stock is currently owned by company insiders.
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fennec Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fennec Pharmaceuticals wasn't on the list.
While Fennec Pharmaceuticals currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
